Updates from the Society for Neuro-Oncology Annual Meeting

Last week, we attended the world's largest brain tumor science fair: the Society for Neuro-Oncology (SNO) Annual Meeting in Miami. 

There were a number of newsworthy presentations, including encouraging clinical trial updates about Tocagen's novel gene therapy and Celldex Therapeautics' investigational immunotherapy.  ABC² has been an early funder and collaborator in both of these efforts. 

Novocure's presentation at SNO resulted in an article by the New York Times about Novocure's novel scalp device that zaps tumors with electrical current.  While we have not funded Novocure's therapy, our friend and colleague, Al Musella, founder of the Musella Foundation, has been an early champion of the Novocure treatment.  Al recently wrote a thought-provoking blog post about the potential impact Novocure's device could have on treating brain tumors in the future.